<table border="0" id="id_74bcf0ec-caf5-484c-b98c-f7b334969c87" width="0.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col></col>
<col></col>
<col></col>
<tbody>
<tr id="id_8953b040-dc22-435f-aa79-013eb0ce1c18" stylecode="Toprule">
<td align="center" stylecode="Lrule Rrule" valign="top">Concomitant Drug<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Effect on  Concentration of Lamotrigine or Concomitant Drug<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Clinical Comment<br/>
</td>
</tr>
<tr id="id_31071dcf-a8c2-48c5-8563-b494af33afaa">
<td align="left" stylecode="Lrule Rrule" valign="top">Estrogen-containing oral contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">
<br/>↓ lamotrigine<br/> <br/> <br/> ↓ levonorgestrel</td>
<td align="left" stylecode="Rrule" valign="top">
<br/>Decreased lamotrigine levels approximately 50%.<br/> <br/>Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr id="id_aedb0e1b-3b5d-48a9-9fd6-fad7bef30f69">
<td align="left" stylecode="Lrule Rrule" valign="top">
<br/>Carbamazepine (CBZ)<br/>and CBZ epoxide</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine<br/>
<br/>  <br/> <br/> ? CBZ epoxide</td>
<td align="left" stylecode="Rrule" valign="top">
<br/>Addition of carbamazepine decreases lamotrigine concentration approximately 40% <br/> <br/>May increase CBZ epoxide levels</td>
</tr>
<tr id="id_da586bba-f1d2-4941-a951-6e6744199344">
<td align="left" stylecode="Lrule Rrule" valign="top">Phenobarbital/Primidone<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.<br/>
</td>
</tr>
<tr id="id_fc4eb301-3407-4475-b946-817edf4fd2b3">
<td align="left" stylecode="Lrule Rrule" valign="top">Phenytoin (PHT)<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.<br/>
</td>
</tr>
<tr id="id_bb279e27-ad59-4ccb-a75e-1d772de81bfc">
<td align="left" stylecode="Lrule Rrule" valign="top">Rifampin<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">Decreased lamotrigine AUC approximately 40%.<br/>
</td>
</tr>
<tr id="id_3eac3ff5-e6b0-480c-9b99-8fc3d0b41590" stylecode="Botrule">
<td align="left" stylecode="Lrule Rrule" valign="top">Valproate<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">
<br/>↑ lamotrigine<br/> <br/> <br/> ? valproate</td>
<td align="left" stylecode="Rrule" valign="top">
<br/>Increased lamotrigine concentrations slightly more than 2-fold.<br/> <br/>Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.</td>
</tr>
</tbody>
</table>